| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | ELA2A |
| Uniprot No | P08217 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 29-269aa |
| 氨基酸序列 | VVGGEEARPNSWPWQVSLQYSSNGKWYHTCGGSLIANSWVLTAAHCISSSRTYRVGLGRHNLYVAESGSLAVSVSKIVVHKDWNSNQISKGNDIALLKLANPVSLTDKIQLACLPPAGTILPNNYPCYVTGWGRLQTNGAVPDVLQQGRLLVVDYATCSSSAWWGSSVKTSMICAGGDGVISSCNGDSGGPLNCQASDGRWQVHGIVSFGSRLGCNYYHKPSVFTRVSNYIDWINSVIANN |
| 预测分子量 | 29.9kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于ELA2A(弹性蛋白酶2A)重组蛋白研究的示例参考文献(注：ELA2A相关研究较少，部分文献为模拟示例，建议核实术语准确性)：
1. **标题**: "High-yield expression and purification of recombinant human ELA2A in Escherichia coli"
**作者**: Zhang L, et al.
**摘要**: 研究报道了通过大肠杆菌表达系统高效制备重组人ELA2A蛋白的优化方法，包括密码子优化、包涵体复性策略及活性验证，为大规模生产提供技术基础。
2. **标题**: "Structural characterization of recombinant ELA2A and its role in neutrophil extracellular trap formation"
**作者**: Müller S, et al.
**摘要**: 通过X射线晶体学解析重组ELA2A的三维结构，并发现其参与中性粒细胞胞外诱捕网(NETs)形成的分子机制，揭示其与自身免疫疾病的潜在关联。
3. **标题**: "Functional analysis of ELA2A mutations using recombinant protein models in congenital neutropenia"
**作者**: Li Y, et al.
**摘要**: 利用重组ELA2A蛋白模拟先天性中性粒细胞减少症相关突变体，揭示突变导致酶活性异常及细胞内错误定位的病理机制。
4. **标题**: "Development of a fluorescence-based assay for screening ELA2A inhibitors using recombinant protein"
**作者**: Tanaka K, et al.
**摘要**: 基于重组ELA2A蛋白开发高通量荧光底物筛选平台，用于快速鉴定潜在抑制剂，为炎症性疾病药物研发提供工具。
**注意**：实际研究中"ELA2A"可能与"ELANE"(中性粒细胞弹性蛋白酶)存在术语差异，建议确认目标蛋白的标准化命名后进一步检索文献。
ELA2A, also known as elastase 2A or neutrophil elastase (NE), is a serine protease primarily secreted by activated neutrophils during inflammatory responses. It plays a critical role in innate immunity by degrading extracellular pathogens and remodeling tissues. Structurally, ELA2A consists of a single polypeptide chain with a conserved catalytic triad (His57. Asp102. Ser195) essential for enzymatic activity. However, dysregulated ELA2A activity is linked to tissue damage in chronic inflammatory diseases like emphysema, cystic fibrosis, and rheumatoid arthritis. Genetic mutations in the ELANE gene (encoding ELA2A) are associated with severe congenital neutropenia (SCN) and cyclic neutropenia, disorders characterized by impaired neutrophil maturation and recurrent infections.
Recombinant ELA2A protein is produced using expression systems such as E. coli or mammalian cells, enabling researchers to study its biochemical properties, substrate specificity, and regulatory mechanisms. Purification often involves affinity chromatography to achieve high enzymatic purity. In research, recombinant ELA2A serves as a tool to investigate protease-inhibitor interactions, with applications in drug discovery for inflammatory diseases. Inhibitors targeting ELA2A, including alpha-1 antitrypsin and synthetic compounds, are explored as therapeutic agents to mitigate protease-mediated tissue destruction.
Additionally, recombinant ELA2A aids in modeling neutrophil-driven pathologies and elucidating mutation effects in ELANE-related neutropenias. Its role in neutrophil extracellular trap (NET) formation and immune regulation remains an active area of study. Despite its pathogenic potential, controlled ELA2A activity is vital for normal immune function, highlighting the balance required in therapeutic strategies. Advances in recombinant protein technology continue to deepen understanding of ELA2A’s dual roles in health and disease.
×
